#3-61E. Balancing Act: Glucocorticoid Safety in ICI-Treated RA Patients (ArthritisRheumatol, 2026)

Do glucocorticoids compromise the life-saving efficacy of immune checkpoint inhibitors (ICIs) in patients with pre-existing autoimmune diseases? This episode examines a pivotal retrospective cohort study of 663 Medicare patients with rheumatoid arthritis (RA) and metastatic non-small cell lung cancer treated with ICIs. The authors investigated whether non-dexamethasone glucocorticoid use during the first 91 days of immunotherapy affected overall survival using complex time-varying models. The study reveals a critical clinical insight: low-dose glucocorticoids—with a median daily prednisone equivalent of 6.6 mg—were not associated with worse survival outcomes, suggesting that managing RA flares with modest steroid doses does not necessarily blunt the anti-tumor immune response. However, critical appraisal is necessary; as a retrospective analysis of administrative claims data, the study lacks definitive clinical details regarding the exact indication for steroid prescriptions, relying instead on prescriber specialty as a proxy for distinguishing between rheumatic management and cancer palliation. Nevertheless, for oncologists and rheumatologists, these findings offer vital reassurance that low-dose steroids can likely be safely utilized to manage comorbid RA symptoms without negating the survival benefits of checkpoint inhibition.

Citation: Jannat-Khah D, et al. Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors? Arthritis & Rheumatology. 2026. DOI: 10.1002/art.43445

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.